40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05680220 |
|
Recruitment Status :
Not yet recruiting
First Posted : January 11, 2023
Last Update Posted : January 11, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation.
In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Major Depressive Disorder Treatment Resistant Depression | Device: Neurostimulation System (NSS): Active Setting Device: Neurostimulation System (NSS): Sham Setting | Not Applicable |
Major depression is a major societal challenge worldwide and a substantial proportion of patients do not attain remission. Major depressive disorder (MDD) bears several key neurobiological similarities with Alzheimer's Disease, namely cognitive deficits, impaired neuroplasticity, neurodegeneration, and neuroinflammation. Inducing neuroplasticity and reducing neuroinflammation are thought to be key cellular targets in the treatment of MDD. However, 40 Hz light stimulation research in the context of MDD is limited.
In this double-blinded, randomized placebo-controlled trial the primary objective is to investigate the antidepressant effect of a non-invasive neurostimulation therapy using a 40 Hz masked flickering light. This study utilizes a novel way of masking light by alternating the spectral composition of white light, resulting in the flicker unnoticeable to human perception.
The primary outcome measure of this study is the estimated difference in the Hamilton Depression Rating sub-scale (HAM-D6) scores between groups at week 6. Furthermore, investigators want to assess whether 40 Hz masked flickering light therapy produces a similar early shift in neural and cognitive response to emotional information seen with antidepressant therapy and whether this predicts treatment efficacy. Suicidal ideation, sleep patterns, and quality of life will be also investigated in order to evaluate the 40 Hz masked flickering light stimulation effects on other symptoms of depression. Explorative analysis of the EEG data will be performed from baseline to week 6 for the further development and validation of EEG-based biomarkers.
A total of 60 participants will be enrolled for a six weeks treatment period followed by a two weeks follow-up period. Participants will be recruited from a psychotherapeutic outpatient unit. Medication should be unchanged for the last 4 weeks and during the study period.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-blinded, Randomized Placebo-controlled Trial of 40 Hz Light Neurostimulation Therapy for Patients With Depression |
| Estimated Study Start Date : | February 2023 |
| Estimated Primary Completion Date : | July 2024 |
| Estimated Study Completion Date : | July 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Active Neurostimulation System (NSS)
Exposure to the NSS device set to 40 Hz invisible spectral flicker 1 hour a day
|
Device: Neurostimulation System (NSS): Active Setting
Exposure to the active device for 1 hour a day for 6 weeks |
|
Placebo Comparator: Sham Neurostimulation System (NSS)
Exposure to the NSS device set to continuous color-matched white light for 1 hour a day
|
Device: Neurostimulation System (NSS): Sham Setting
Exposure to the sham device for 1 hour a day for 6 weeks |
- Depression severity measured by Hamilton Depression Rating sub-scale (HAM-D6) [ Time Frame: Baseline and week 6 ]The HAM-D6 scale is designed to rate the severity of depression by a healthcare professional. The assessment scale contains 6 items pertaining to the symptoms of depression experienced over the week. The primary endpoint is the mean difference in scores between treatments at baseline and week 6. The score range is from, 0-24 (24=highest depression level).
- Self-reported depression symptoms measured by Major Depression Inventory (MDI) [ Time Frame: Baseline, week 1, 3, 6 and 8. ]The MDI is a depression self-assessment questionnaire. It consists of the 10 ICD-10 symptoms for depression. The sum of 10 questions indicates the degree of depression. The score range is from 0-50 (50=highest depression level).
- Cognition measured by Facial Expression Recognition Test (FERT) [ Time Frame: Baseline, week 1 and 6 ]
Assessing attention and recognition of emotional facial expressions using the FERT.
The outcome is accuracy (% correct expressions identified, range: 0-100, higher is better) and response times for accurate identifications (milliseconds, range can vary quite a bit, smaller number is better because it reflect higher speed).
- Cognition measured by Emotional Categorization and Memory test (ECMT) [ Time Frame: Baseline, week 1 and 6 ]Assessing self-referent memory for emotional words using the ECMT. Outcome is response times for correct identifications during encoding phase (milliseconds, smaller better) and for recall phase: number of positive and negative words recalled (higher is better)
- Cognition measured by Screen for Cognitive Impairment in Psychiatry (SCIP) [ Time Frame: Baseline, week 1 and 6 ]Non-emotional cognition is investigated with the SCIP. Outcomes is total score as well as scores for the five subtests, in all cases higher is better (numbers correct)
- Cognition measured by Trail Making Test B (TMT- B) [ Time Frame: Baseline, week 1 and 6 ]Non-emotional cognition investigated with the Trail Making Test B (TMT- B). Outcome is time in seconds to complete the task, lower is better (higher speed)
- Sleep quality measured by Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: Baseline, week 3, 6 and 8 ]PSQI consist of seven component scores that are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality. A cut-off of 5 is recognized a indicative of sleep problems.
- Sleep duration [ Time Frame: Baseline, week 3, 6 and 8 ]Average sleep duration assessed over last 7 days will be logged by the participants using a sleep diary.
- Sleep timing [ Time Frame: Baseline, week 3, 6 and 8 ]Average sleep timing will be assessed over last 7 days logged by the participants using a sleep diary.
- Quality of Life measured by WHO quality of life index (WHO-5) [ Time Frame: Baseline, week 3,6 and 8 ]The WHO-5 score ranges from 0 to 25, with 0 representing worst possible and 25 representing best possible quality of life. To obtain a percentage score ranging from 0 to 100, the raw score is multiplied by 4. A percentage score of 0 represents worst possible, whereas a score of 100 represents best possible quality of life. A 10% difference indicates a significant change.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects between 18 and 75 years of age.
- Subjects with a diagnosis of major depressive episode and currently experiencing a depressive episode according to DSM-5
- Subjects with an MDI score > 21 at screening
- Subjects on stable medication and/or psychotherapy for at least 4 weeks before starting the trial.
- Subjects, who are willing to comply with the scheduled plan and are able to use the device for 1 hour per day for 6 weeks.
- Subjects who can understand the oral and written study information and willing to sign an informed consent.
Exclusion Criteria:
- Subjects with a history of photosensitive migraines and/or epileptic seizures
- Subjects with a known eye disorder that might be sensitive to light treatment.
- Subjects with a known history of bipolar disorder according to DSM-5 criteria
- Subjects with suicidal ideation corresponding to a score of 2 or more on the HAM-D 17 scale item 3 or if the patient or investigator is uncertain of the degree of suicidal risk
- Subjects with current psychotic symptoms. However, subjects with a prior psychotic depression or subjects with an actual psychotic depression episode that at the time of informed consent no longer fulfills the psychosis criteria are allowed to participate.
- Subjects with current drug or alcohol dependence based on their medical records or the M.I.N.I. interview.
- Subjects with a known history of borderline personality disorder
- Subjects currently enrolled in another investigational treatment study.
- Subjects with progressive neurodegenerative or neoplastic disease.
- Subjects who are unable to understand the study procedures or handling of the NSS device.
- Subjects who are pregnant at the time of inclusion or unsafe contraception in women of fertile age
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05680220
| Contact: Klaus Martiny | +45 38 64 71 00 | klaus.martiny@regionh.dk | |
| Contact: Malina Ploug Larsen | malina.ploug.larsen@regionh.dk |
| Denmark | |
| Mental Health Centre Copenhagen | |
| Copenhagen, Denmark, 2100 | |
| Principal Investigator: | Klaus Martiny | Senior Consultant at Psychiatric Centre Copenhagen |
Other Publications:
| Responsible Party: | Klaus Martiny, Professor, Head of NID-Group, Mental Health Services in the Capital Region, Denmark |
| ClinicalTrials.gov Identifier: | NCT05680220 |
| Other Study ID Numbers: |
FELIX |
| First Posted: | January 11, 2023 Key Record Dates |
| Last Update Posted: | January 11, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
40 Hz stimulation Major Depressive Disorder Light therapy GENUS |
|
Depression Depressive Disorder Depressive Disorder, Major Depressive Disorder, Treatment-Resistant |
Behavioral Symptoms Mood Disorders Mental Disorders |